Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ:LGND) and maintained a price target of $95.
June 28, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Ligand Pharmaceuticals and maintained a price target of $95.
The reiteration of a Buy rating and the maintenance of a $95 price target by a reputable analyst is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100